{"id":208956,"date":"2025-10-13T04:09:06","date_gmt":"2025-10-13T04:09:06","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/208956\/"},"modified":"2025-10-13T04:09:06","modified_gmt":"2025-10-13T04:09:06","slug":"utility-of-ga68-psma-pet-ct-in-detecting-biochemical-recurrence-of-prostate-cancer-egyptian-journal-of-radiology-and-nuclear-medicine","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/208956\/","title":{"rendered":"Utility of Ga68-PSMA PET\/CT in detecting biochemical recurrence of prostate cancer | Egyptian Journal of Radiology and Nuclear Medicine"},"content":{"rendered":"<p>Prostate cancer (PC) is the second most common cancer among men worldwide, and it is also the fifth most fatal malignancy among men globally [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 1\" title=\"Barsouk A, Padala SA, Vakiti A et al (2020) Epidemiology, staging and management of prostate cancer. Med Sci (Basel) 8(3):28\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR1\" id=\"ref-link-section-d424994406e2951\" rel=\"nofollow noopener\" target=\"_blank\">1<\/a>]. Monitoring prostate-specific antigen (PSA) levels during follow-up is a widely accepted and cost-effective method for detecting prostate cancer relapse [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 8\" title=\"Kunikowska J, Pe\u0142ka K, Tayara O et al (2022) Ga-68-PSMA-11 PET\/CT in patients with biochemical recurrence of prostate cancer after primary treatment with curative intent-impact of delayed imaging. J Clin Med 11:12\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR8\" id=\"ref-link-section-d424994406e2954\" rel=\"nofollow noopener\" target=\"_blank\">8<\/a>].<\/p>\n<p>Ga68-PSMA PET\/CT was recently recommended for use in patients with PC. Multiple studies have found it to have superior diagnostic accuracy, specificity, and sensitivity compared to other traditional imaging methods for confirming biochemical recurrence in large patient populations with recurrent PC [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 4\" title=\"Fendler WP, Weber M, Iravani A et al (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25(24):7448\u20137454\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR4\" id=\"ref-link-section-d424994406e2960\" rel=\"nofollow noopener\" target=\"_blank\">4<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 5\" title=\"Shore ND, Moul JW, Pienta KJ et al (2024) Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis 27(2):192\u2013201\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR5\" id=\"ref-link-section-d424994406e2963\" rel=\"nofollow noopener\" target=\"_blank\">5<\/a>].<\/p>\n<p>This research aimed to evaluate the role of Ga68-PSMA in the biochemical recurrence of prostate cancer.<\/p>\n<p>In the current study, the recurrence was higher among the high socioeconomic class.<\/p>\n<p>This result is in concordance with that of Coughlin [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 9\" title=\"Coughlin SS (2020) A review of social determinants of prostate cancer risk, stage, and survival. Prostate Int 8(2):49\u201354\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR9\" id=\"ref-link-section-d424994406e2976\" rel=\"nofollow noopener\" target=\"_blank\">9<\/a>], who stated that socioeconomic factors play a role in influencing the risk of prostate cancer. Incidence rates of prostate cancer tend to be positively associated with higher socioeconomic status. In comparison, lower socioeconomic status is often linked to an increased risk of lower survival rates among individuals diagnosed with prostate cancer [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424\" href=\"#ref-CR10\" id=\"ref-link-section-d424994406e2979\">10<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Stolzenbach LF, Deuker M, Coll\u00e0-Ruvolo C et al (2021) Radical prostatectomy improves survival in selected metastatic prostate cancer patients: a North American population-based study. Int J Urol 28(8):834\u2013839\" href=\"#ref-CR11\" id=\"ref-link-section-d424994406e2979_1\">11<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 12\" title=\"da Cruz JAS, Passerotti CC, Dos Reis ST et al (2017) Is age an independent factor for prostate cancer? A paired analysis. Curr Urol 9(4):183\u2013187\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR12\" id=\"ref-link-section-d424994406e2982\" rel=\"nofollow noopener\" target=\"_blank\">12<\/a>].<\/p>\n<p>The residence of the patient is another point here in the current study, where urban residency was found to be associated with a higher recurrence of prostate cancer than rural residency. This finding is in disagreement with that of Stolzenbach et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 11\" title=\"Stolzenbach LF, Deuker M, Coll\u00e0-Ruvolo C et al (2021) Radical prostatectomy improves survival in selected metastatic prostate cancer patients: a North American population-based study. Int J Urol 28(8):834\u2013839\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR11\" id=\"ref-link-section-d424994406e2988\" rel=\"nofollow noopener\" target=\"_blank\">11<\/a>], who found that individuals living in rural areas have a higher incidence of prostate cancer and its complications. Our result represents a small sample size and could be related to the cultural aspects of urban areas that may differ from that of Stolzenbach et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 11\" title=\"Stolzenbach LF, Deuker M, Coll\u00e0-Ruvolo C et al (2021) Radical prostatectomy improves survival in selected metastatic prostate cancer patients: a North American population-based study. Int J Urol 28(8):834\u2013839\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR11\" id=\"ref-link-section-d424994406e2991\" rel=\"nofollow noopener\" target=\"_blank\">11<\/a>] study.<\/p>\n<p>In the present study, radical prostatectomy was the surgical option for 73.3% of cases. Twenty percent of our patients received postoperative radiotherapy with a mean PORT dose (Gy) of 65.33\u2009\u00b1\u20093.07. The objective of post-prostatectomy radiation therapy is to minimize the risk or prevent the recurrence of cancer in the prostate bed [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 13\" title=\"Pisansky TM, Hunt D, Gomella LG et al (2015) Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol 33(4):332\u2013339\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR13\" id=\"ref-link-section-d424994406e2997\" rel=\"nofollow noopener\" target=\"_blank\">13<\/a>].<\/p>\n<p>ADT was used in 56.7% of our patients, with a mean duration of therapy of 34.54\u2009\u00b1\u200924.4 months. In a study done by Dorff et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 14\" title=\"Dorff TB, Flaig TW, Tangen CM et al (2011) Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 29(15):2040\u20132045\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR14\" id=\"ref-link-section-d424994406e3003\" rel=\"nofollow noopener\" target=\"_blank\">14<\/a>], they found that two years of\u00a0ADT was likely a significant contributor to improved outcomes after radical prostatectomy. The utilization of PSA for identifying recurrent disease has been in practice for over 35 years [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 15\" title=\"Toussi A, Stewart-Merrill SB, Boorjian SA et al (2016) Standardizing the definition of biochemical recurrence after radical prostatectomy\u2014What prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression? J Urol 195(6):1754\u20131759\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR15\" id=\"ref-link-section-d424994406e3006\" rel=\"nofollow noopener\" target=\"_blank\">15<\/a>].<\/p>\n<p>In the current study, the mean of the biochemical recurrence-free interval was 56.1\u2009\u00b1\u200934.03 months, with the mean PSA value in the first measurement and the confirmatory level being 34.62\u2009\u00b1\u2009120.08 and 35.81\u2009\u00b1\u2009123.8 (ng\/ml), respectively. These results matched those reported by Jemal et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 16\" title=\"Jemal A, Fedewa SA, Ma J et al (2015) Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 314(19):2054\u20132061\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR16\" id=\"ref-link-section-d424994406e3012\" rel=\"nofollow noopener\" target=\"_blank\">16<\/a>]. The rising levels in the current study are in agreement with those of Fossati\u00a0et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 17\" title=\"Fossati N, Rossi MS, Cucchiara V et al (2017) Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely? Urol Oncol 35(4):150-e159\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR17\" id=\"ref-link-section-d424994406e3015\" rel=\"nofollow noopener\" target=\"_blank\">17<\/a>], who mentioned that an increasing PSA level was the initial indicator of disease progression following radical prostatectomy (RP).<\/p>\n<p>Regardless of the BCR definition, it should not be used as a landmark to start treatments [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 18\" title=\"Nasser NJ, Chernyak V, Shankar V et al (2021) Predictors of prostate bed recurrence on magnetic resonance imaging in patients with rising prostate-specific antigen after radical prostatectomy. Can Urol Assoc J 15(1):E22-e28\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR18\" id=\"ref-link-section-d424994406e3021\" rel=\"nofollow noopener\" target=\"_blank\">18<\/a>], so in the current study, we used\u00a0Ga68-PSMA PET\/CT to further evaluate BCR.<\/p>\n<p>In the current study, surgical bed recurrence occurred in 30% of patients. In addition, local LN deposits were found in 33.3% of patients, while distant LN deposits were found in 23.3%. Furthermore, bone metastasis was the most common distant metastasis found in 30% of our patients.<\/p>\n<p>In this domain, the results of the current study were plotted against the results from other centers where Nasser et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 18\" title=\"Nasser NJ, Chernyak V, Shankar V et al (2021) Predictors of prostate bed recurrence on magnetic resonance imaging in patients with rising prostate-specific antigen after radical prostatectomy. Can Urol Assoc J 15(1):E22-e28\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR18\" id=\"ref-link-section-d424994406e3031\" rel=\"nofollow noopener\" target=\"_blank\">18<\/a>] found that prostate bed recurrence was observed in\u00a015% of patients, 29% of patients had local lymph node recurrence, and 13% of patients had\u00a0distant lymph node metastasis. On the other hand, Ilhan et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 19\" title=\"Ilhan H, Kroenke M, Wurzer A et al (2022) (18)F-RHPSMA-7 pet for the detection of biochemical recurrence of prostate cancer after curative-intent radiation therapy: a bicentric retrospective study. J Nucl Med 63(8):1208\u20131214\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR19\" id=\"ref-link-section-d424994406e3034\" rel=\"nofollow noopener\" target=\"_blank\">19<\/a>] reported that local recurrence was observed in 80% (78 out of 97 cases), while pelvic lymph node metastases were identified in 38% (37 out of 97 cases).<\/p>\n<p>Prostatectomy bed recurrence (local relapse) occurred in 30%, regional relapse occurred in 33.3%, and distant relapse was recorded in 30% of our studied patients. These results were greater than those previously reported by Calais et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 20\" title=\"Calais J, Fendler WP, Eiber M et al (2018) Impact of (68)Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 59(3):434\u2013441\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR20\" id=\"ref-link-section-d424994406e3040\" rel=\"nofollow noopener\" target=\"_blank\">20<\/a>] and Emmett et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 21\" title=\"Emmett L, van Leeuwen PJ, Nandurkar R et al (2017) Treatment outcomes from (68)Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET. J Nucl Med 58(12):1972\u20131976\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR21\" id=\"ref-link-section-d424994406e3043\" rel=\"nofollow noopener\" target=\"_blank\">21<\/a>], who found that the frequency of prostatectomy bed recurrence was 17.5% and 23%, respectively. On the other hand, our results were lower than those reported by Moore et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 22\" title=\"Moore CM, Giganti F, Albertsen P et al (2017) Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the precise recommendations\u2014a report of a European School of Oncology Task Force. Eur Urol 71(4):648\u2013655\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR22\" id=\"ref-link-section-d424994406e3046\" rel=\"nofollow noopener\" target=\"_blank\">22<\/a>], who found that the recurrence pattern after RP was predominantly local (\u224860%).<\/p>\n<p>The differences between these and our study results could be attributed to the time our patients sought medical follow-up and the difference in several studied patients.<\/p>\n<p>Regarding the type of relapse, this study revealed that bone relapse only was the most common distant relapse and was detected in (16.6%) of patients, followed by bone and visceral relapse reported in (13.3%) of the studied patients.<\/p>\n<p>These findings are nearly similar to those reported by Szigeti et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 23\" title=\"Szigeti F, Schweighofer-Zwink G, Meissnitzer M et al (2022) Incremental impact of [(68) Ga]Ga-PSMA-11 PET\/CT in primary N and M staging of prostate cancer prior to curative-intent surgery: a prospective clinical trial in comparison with mpMRI. Mol Imaging Biol 24(1):50\u201359\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR23\" id=\"ref-link-section-d424994406e3058\" rel=\"nofollow noopener\" target=\"_blank\">23<\/a>], who found bone metastases (BM) in 14.8% (12\/81) of the patients on Ga68-PSMA\u2014PET CT; 6 patients had BM in the pelvic region.<\/p>\n<p>In the present study, regional relapse was the most common relapse (representing 23.3% of patients); it is worth mentioning that a group of patients in our study developed both local relapse and distant relapse (representing 13.3% of patients) while a group of patients developed local relapse only (representing 10% of patients). Our findings were in concordance with those reported by Von Eyben et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 24\" title=\"von Eyben FE, Kairemo K, Paller C et al (2021) (177)Lu-PSMA Radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials. Biomedicines 9(8):1042\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR24\" id=\"ref-link-section-d424994406e3065\" rel=\"nofollow noopener\" target=\"_blank\">24<\/a>], who found that 30% of patients had a regional relapse, followed by distant relapse in 20% and local relapse in 13% of patients.<\/p>\n<p>PET metrics include qualitative assessment indices, such as the maximum standardized uptake value (SUVmax). In the current study, we studied this point about SUVmax, and the highest SUVmax mean was 45 in a patient with rectal invasion relapse, and the lowest SUVmax mean was 5.12\u2009\u00b1\u20090.81 in patients with lung deposits. This came in agreement with Eder et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 25\" title=\"Eder M, Neels O, M\u00fcller M et al (2014) Novel preclinical and radiopharmaceutical aspects of [68ga]Ga-PSMA-HBED-CC: a new pet tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 7(7):779\u2013796\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR25\" id=\"ref-link-section-d424994406e3071\" rel=\"nofollow noopener\" target=\"_blank\">25<\/a>], who reported that the lowest SUVmax mean was 2.49\u2009\u00b1\u20090.27 in patients with lung deposits, while they found that the highest SUVmax mean was 139.4\u2009\u00b1\u200921.4 in patients who had kidney relapse.<\/p>\n<p>Pepe et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 26\" title=\"Pepe P, Pepe L, Tamburo M et al (2023) (68)Ga-PSMA PET\/CT and prostate cancer diagnosis: Which Suvmax value? In Vivo 37(3):1318\u20131322\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR26\" id=\"ref-link-section-d424994406e3077\" rel=\"nofollow noopener\" target=\"_blank\">26<\/a>] stated that Ga68-PSMA PET\/CT, utilizing an SUVmax cutoff of 8, exhibited high accuracy in diagnosing prostate cancer (PC), achieving 100% accuracy in the presence of Gleason Grade (GG)\u2009\u2265\u20093. This suggests a favorable cost\u2013benefit ratio, positioning it as a comprehensive and efficient procedure for both the diagnosis and staging of high-risk prostate cancer.<\/p>\n<p>In our study, the PSA level was significantly higher in patients who had relapses than those without (55.46\u2009\u00b1\u2009150.9 vs 0.24\u2009\u00b1\u20090.04). This finding is in concordance with that of David and\u00a0Leslie\u00a0[<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 27\" title=\"David MK, Leslie SW. Prostate Specific Antigen. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.; 2024.\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR27\" id=\"ref-link-section-d424994406e3083\" rel=\"nofollow noopener\" target=\"_blank\">27<\/a>] who reported that PSA levels were higher in recurrence cases than those without recurrence, and the elevation in PSA levels typically serves as the initial indicator of recurrent prostate cancer.<\/p>\n<p>Szymaniak\u00a0et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 28\" title=\"Szymaniak JA, Washington SL 3rd, Cowan JE et al (2023) The natural history of a delayed detectable PSA after radical prostatectomy. Prostate Cancer Prostatic Dis 26(4):759\u2013764\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR28\" id=\"ref-link-section-d424994406e3089\" rel=\"nofollow noopener\" target=\"_blank\">28<\/a>] reported that a rising PSA level after prostatectomy indicates PC recurrence, a finding that supports the current study\u2019s results. In addition, Mapelli et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 29\" title=\"Mapelli P, Ghezzo S, Pini C et al (2023) Predictors of PSMA PET positivity: analysis in a selected cohort of biochemical recurrence prostate cancer patients after radical prostatectomy. Cancers (Basel) 15(18):4589\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR29\" id=\"ref-link-section-d424994406e3092\" rel=\"nofollow noopener\" target=\"_blank\">29<\/a>] consider rising PSA a predictor of prostate cancer recurrence. These findings agree with ours.<\/p>\n<p>In the current study, prostate cancer patients with regional relapse had the highest first and confirmatory PSA levels (85.14\u2009\u00b1\u20094.95 and 88.1\u2009\u00b1\u2009225.3 ng\/ml, respectively), while patients with local relapse had the lowest first and confirmatory PSA levels (3.68\u2009\u00b1\u20094.95 and 3.93\u2009\u00b1\u20095.09 ng\/ml, respectively).<\/p>\n<p>This aligns with the findings of Oyama et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 30\" title=\"Oyama N, Miller TR, Dehdashti F et al (2003) 11c-acetate pet imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44(4):549\u2013555\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR30\" id=\"ref-link-section-d424994406e3102\" rel=\"nofollow noopener\" target=\"_blank\">30<\/a>], who stated that higher PSA level in PC patients was associated with a high likelihood of regional relapse.<\/p>\n<p>Our results showed that Ga68-PSMA PET\/CT at a cutoff level\u2009\u2265\u20090.3 ng\/ml could detect early prostate cancer relapses with 94.7% sensitivity, 81.8% specificity, 90% PPV, and 90% NPV. The accuracy of early diagnosis of prostate cancer relapse was 90%.<\/p>\n<p>Our results in this domain agreed with those of Fendler et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 4\" title=\"Fendler WP, Weber M, Iravani A et al (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25(24):7448\u20137454\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR4\" id=\"ref-link-section-d424994406e3111\" rel=\"nofollow noopener\" target=\"_blank\">4<\/a>], who reported that even when serum levels of PSA are low, Ga68-PSMA PET\/CT can accurately detect prostate cancer relapse. Furthermore, our findings are consistent with those of Haidar et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 31\" title=\"Haidar M, Abi-Ghanem AS, Moukaddam H et al (2022) (68)Ga-PSMA PET\/CT in early relapsed prostate cancer patients after radical therapy. Sci Rep 12(1):20500\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR31\" id=\"ref-link-section-d424994406e3114\" rel=\"nofollow noopener\" target=\"_blank\">31<\/a>], who reported that Ga68-PSMA PET\/CT successfully detected prostate cancer recurrence in patients undergoing biochemical recurrence (BCR) and that there was a strong correlation between the PET scan\u2019s positivity and the patient\u2019s PSA level on the day of the scan.<\/p>\n<p>Consistent with our findings, a surgical series in a meta-analysis on diagnosing lymph node metastases using Ga68-PSMA PET\/CT found a significant specificity rate of 97% and a moderate sensitivity rate of 60% [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 24\" title=\"von Eyben FE, Kairemo K, Paller C et al (2021) (177)Lu-PSMA Radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials. Biomedicines 9(8):1042\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR24\" id=\"ref-link-section-d424994406e3120\" rel=\"nofollow noopener\" target=\"_blank\">24<\/a>].<\/p>\n<p>Other researchers have investigated the sensitivity of Ga68-PSMA PET\/CT, revealing high sensitivity and excellent specificity for detecting prostate cancer, particularly in cases of recurrent disease, even at very low levels of PSA ranging from 0.2 to 0.5 ng\/ml [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 32\" title=\"Bud\u00e4us L, Leyh-Bannurah SR, Salomon G et al (2016) Initial experience of (68)Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69(3):393\u2013396\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR32\" id=\"ref-link-section-d424994406e3126\" rel=\"nofollow noopener\" target=\"_blank\">32<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 33\" title=\"Rauscher I, D\u00fcwel C, Haller B et al (2018) Efficacy, predictive factors, and prediction nomograms for (68)Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol 73(5):656\u2013661\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR33\" id=\"ref-link-section-d424994406e3129\" rel=\"nofollow noopener\" target=\"_blank\">33<\/a>]. These studies supported our findings.<\/p>\n<p>To compare our findings in sensitivity and specificity of Ga68-PSMA PET\/CT, we found that another study by Kwan et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 34\" title=\"Kwan TN, Spremo S, Teh AYM et al (2021) Performance of Ga-68 PSMA PET\/CT for diagnosis and grading of local prostate cancer. Prostate Int 9(2):107\u2013112\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR34\" id=\"ref-link-section-d424994406e3135\" rel=\"nofollow noopener\" target=\"_blank\">34<\/a>] found a high sensitivity of Ga68-PSMA PET\/CT for the detection of post-radical prostatectomy relapse: 81.2%.<\/p>\n<p>In addition, Maurer et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 35\" title=\"Maurer T, Eiber M, Schwaiger M et al (2016) Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 13(4):226\u2013235\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR35\" id=\"ref-link-section-d424994406e3142\" rel=\"nofollow noopener\" target=\"_blank\">35<\/a>] mentioned that the applications of Ga68-PSMA PET\/CT are varied, encompassing improved detection of new metastases and the identification of cancer in cases of biochemical recurrence.<\/p>\n<p>In another study done by Yan\u00a0et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 36\" title=\"Yan L, Zhang Z, Wang T et al (2023) Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review. Front Oncol 13:1179595\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR36\" id=\"ref-link-section-d424994406e3148\" rel=\"nofollow noopener\" target=\"_blank\">36<\/a>], they demonstrated that Ga68-PSMA PET\/CT had a sensitivity of 60%, a specificity of 91%, and an accuracy of 83% for detecting pelvic lymph node metastasis. In a more extensive study involving 319 patients and analyzing a mixed patient population retrospectively, Ga68-PSMA PET\/CT demonstrated a sensitivity of 76.6% and a specificity of 100% [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 37\" title=\"Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET\/CT Imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197\u2013209\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR37\" id=\"ref-link-section-d424994406e3151\" rel=\"nofollow noopener\" target=\"_blank\">37<\/a>].<\/p>\n<p>In the current study, the biochemical recurrence-free interval among patients with no relapse was significantly longer when compared with that of patients who had relapse (75.54\u2009\u00b1\u200931.06 vs 44.84\u2009\u00b1\u200931.07 months, p\u2009=\u20090.01). In addition, we found that the mean biochemical recurrence-free interval for patients who had PSA\u2009&lt;\u20090.3 ng\/ml was significantly longer when compared to that of patients who had PSA\u2009&gt;\u20090.3 ng\/ml (119 vs 50 months, p\u2009=\u20090.001). In this regard, our findings matched those of Freedland et al. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 38\" title=\"Freedland SJ, Humphreys EB, Mangold LA et al (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176(4):1404\u20131408\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR38\" id=\"ref-link-section-d424994406e3163\" rel=\"nofollow noopener\" target=\"_blank\">38<\/a>], who reported that early biochemical recurrence (BCR) has been linked to a heightened risk of recurrence and death from prostate cancer.<\/p>\n<p>In another study, a reduced period from surgery to biochemical recurrence (BCR) has been reported as an independent predictor of metastatic progression, relapse, cancer-specific mortality, and overall mortality [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 39\" title=\"Pompe RS, Smith A, Bandini M et al (2018) Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged \u226450 years: a population-based study. Prostate Cancer Prostatic Dis 21(1):71\u201377\" href=\"http:\/\/ejrnm.springeropen.com\/articles\/10.1186\/s43055-025-01516-y#ref-CR39\" id=\"ref-link-section-d424994406e3169\" rel=\"nofollow noopener\" target=\"_blank\">39<\/a>].<\/p>\n<p>Our retrospective study has several limitations: our relatively small (30 patients). This could limit the generalization of the current results. Patients whose PSMA PET\/CT results were positive or negative should have their long-term outcomes evaluated later; our group is still being followed up. There should be a plethora of prospective randomized trials because the data that are now available are insufficient.<\/p>\n","protected":false},"excerpt":{"rendered":"Prostate cancer (PC) is the second most common cancer among men worldwide, and it is also the fifth&hellip;\n","protected":false},"author":2,"featured_media":208957,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[49,48,101771,84,101775,101777,101776,101773,101772,101774],"class_list":{"0":"post-208956","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-ca","9":"tag-canada","10":"tag-ga68","11":"tag-health","12":"tag-imaging-radiology","13":"tag-interventional-radiology","14":"tag-nuclear-medicine","15":"tag-pet-ct","16":"tag-prostate-specific-membrane-antigen","17":"tag-prostatic-cancer"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/208956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=208956"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/208956\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/208957"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=208956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=208956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=208956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}